HLS Therapeutics Inc.
TSX:HLS.TODrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $116.32M
- Beta
- 0.85
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.33
Volume 0.04M
Average 0.01M
HLS.TO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
HLS Therapeutics Inc.TSX: HLS.TO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How HLS.TO compares with its peers on the latest reported figures
- HLS.TO's LTM Mar 2026 research & development of $0 is the lowest of the 7 companies compared; the peer median is $96.85M.
- Research & development amounts to 0.0% of revenue for HLS.TO, versus a peer median of 9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.27B | +80515.8% | -26.7% | — | |
| LTM Jun 2026 | $634M | +1.3% | +5.9% | 5.8% | |
| LTM Jun 2026 | $177.66M | -15.0% | -3.7% | 5.7% | |
| LTM Mar 2026 | $16.04M | -18.6% | -0.6% | 31.9% | |
| LTM Mar 2026 | $8.48M | +125.2% | +24.8% | 9.8% | |
| LTM Mar 2026 | $5.73M | +15.7% | -5.9% | 13.7% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding HLS.TO) | $96.85M | +8.5% | -2.1% | 9.8% | |
Competitors are the stored peer set for HLS.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 60.01M | 61.47M | 63.07M | 56.62M | 56.47M |
| Cost of Revenue | 3.97M | 4.98M | 7.62M | 9M | 32.46M |
| Gross Profit | 56.04M | 56.49M | 55.45M | 47.62M | 24.01M |
| Gross Margin | 93.4% | 91.9% | 87.9% | 84.1% | 42.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 32.06M | 35.58M | 28.29M | 26.93M | 22M |
| Operating Expenses | 62.32M | 69.98M | 55.45M | 55.31M | 28.19M |
| Depreciation & Amortization | 30.26M | 34.4M | 31.94M | 22.72M | 22.2M |
| EBITDA | 25.41M | 18M | 12.88M | 17.22M | 18.02M |
| EBITDA Margin | 42.3% | 29.3% | 20.4% | 30.4% | 31.9% |
| Operating Income | (6.24M) | (13.44M) | (10.35M) | (7.69M) | (4.18M) |
| Operating Margin | -10.4% | -21.9% | -16.4% | -13.6% | -7.4% |
| Interest Income | 44K | 57K | 350K | 319K | 108.87K |
| Interest Expense | 6.96M | 7.32M | 8.75M | 10.08M | 7.22M |
| Other Income / Expenses | (5.52M) | (10.23M) | (17.45M) | (7.9M) | (8.92M) |
| Income Before Tax | (11.81M) | (23.72M) | (27.8M) | (15.58M) | (13.1M) |
| Pre-Tax Margin | -19.7% | -38.6% | -44.1% | -27.5% | -23.2% |
| Income Tax Expense | 1.31M | (124K) | (272K) | 4.07M | (452.79K) |
| Net Income | (13.12M) | (23.6M) | (27.53M) | (19.66M) | (12.65M) |
| Net Margin | -21.9% | -38.4% | -43.6% | -34.7% | -22.4% |
| EPS (Basic) | (0.41) | (0.73) | (0.85) | (0.62) | (0.40) |
| EPS (Diluted) | (0.41) | (0.73) | (0.85) | (0.62) | (0.40) |
| Weighted Avg Shares | 32.18M | 32.33M | 32.26M | 31.84M | 31.53M |
| Weighted Avg Shares (Diluted) | 32.18M | 32.43M | 32.26M | 31.84M | 31.53M |
HLS Therapeutics Inc.
TSX:HLS.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.